| Literature DB >> 31139453 |
Anirudh Kumar1,2, Dan Schwarz1,3,4,5,6, Bibhav Acharya1,7, Pawan Agrawal1, Anu Aryal1, Nandini Choudhury1, David Citrin1,2,8,9,10, Binod Dangal1, Grace Deukmedjian1,11,12, Meghnath Dhimal13, Santosh Dhungana1, Bikash Gauchan1,11, Tula Gupta1, Scott Halliday1,10, Dhiraj Jha1,14, S P Kalaunee1,15, Biraj Karmacharya16,17,18, Sandeep Kishore2,19, Bhagawan Koirala20, Lal Kunwar21, Ramesh Mahar1, Sheela Maru1,2,22,23, Stephen Mehanni1,11,24, Isha Nirola25, Sachit Pandey1, Bhaskar Pant26, Mandeep Pathak1, Sanjaya Poudel1, Irina Rajbhandari1, Anant Raut1, Pragya Rimal1,11, Ryan Schwarz1,3,4,27, Archana Shrestha28,29, Aradhana Thapa1, Poshan Thapa30, Roshan Thapa1, Lena Wong1,11,31, Duncan Maru1,2,23,32,33.
Abstract
Low-income and middle-income countries are struggling with a growing epidemic of non-communicable diseases. To achieve the Sustainable Development Goals, their healthcare systems need to be strengthened and redesigned. The Starfield 4Cs of primary care-first-contact access, care coordination, comprehensiveness and continuity-offer practical, high-quality design options for non-communicable disease care in low-income and middle-income countries. We describe an integrated non-communicable disease intervention in rural Nepal using the 4C principles. We present 18 months of retrospective assessment of implementation for patients with type II diabetes, hypertension and chronic obstructive pulmonary disease. We assessed feasibility using facility and community follow-up as proxy measures, and assessed effectiveness using singular 'at-goal' metrics for each condition. The median follow-up for diabetes, hypertension and chronic obstructive pulmonary disease was 6, 6 and 7 facility visits, and 10, 10 and 11 community visits, respectively (0.9 monthly patient touch-points). Loss-to-follow-up rates were 16%, 19% and 22%, respectively. The median time between visits was approximately 2 months for facility visits and 1 month for community visits. 'At-goal' status for patients with chronic obstructive pulmonary disease improved from baseline to endline (p=0.01), but not for diabetes or hypertension. This is the first integrated non-communicable disease intervention, based on the 4C principles, in Nepal. Our experience demonstrates high rates of facility and community follow-up, with comparatively low lost-to-follow-up rates. The mixed effectiveness results suggest that while this intervention may be valuable, it may not be sufficient to impact outcomes. To achieve the Sustainable Development Goals, further implementation research is urgently needed to determine how to optimise non-communicable disease interventions.Entities:
Keywords: delivery of health care, integrated; global health; implementation research; nepal; non-communicable diseases
Year: 2019 PMID: 31139453 PMCID: PMC6509610 DOI: 10.1136/bmjgh-2018-001343
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Figure 1Enrolment of patient cohorts and inclusion within cohort analysis. COPD, chronic obstructive pulmonary disease; LTFU, loss-to-follow-up; NCD, non-communicable disease.
Clinical definitions of ‘at-goal’ status for each intervention condition
| Non-communicable disease | Management metric | ‘At-goal’ definition |
| Type II diabetes mellitus | Haemoglobin A1c OR fasting blood sugar | Haemoglobin A1c <7.5 OR fasting blood sugar <130* |
| Hypertension | Blood pressure | Systolic blood pressure <130 mm Hg or patient-tailored goal per risk stratification† |
| Chronic obstructive pulmonary disease | Exacerbation status | <2/3 Anthonisen criteria‡ |
*Type II diabetes mellitus: The 2018 American Diabetes Association guidelines32 call for a goal A1c <7% for most patients or A1c <8% in ‘patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, extensive comorbid conditions, or long-standing diabetes in whom the goal is difficult to achieve despite diabetes self-management education, appropriate glucose monitoring, and effective doses of multiple glucose-lowering agents including insulin’. For our clinicians, we established 7.5% as our goal to pragmatically accommodate both populations.
†Hypertension: Based on the 2017 update to the Joint National Committee-7 guidelines,33 we established <130 mm Hg as a default treatment goal, with patient-tailored goals for select patients (≥65 years of age, multiple comorbidities, limited life expectancy, clinical judgement, patient preference).
‡Chronic obstructive pulmonary disease (COPD): The 2017 update to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines‡, 53 define COPD exacerbation as an ‘acute worsening of respiratory symptoms that results in additional therapy’. We used the Anthonisen criteria of worsening sputum volume, sputum purulence and increased dyspnoea to define the ‘worsening of respiratory symptoms’ specified in the GOLD guidelines. We established a threshold of no more than one Anthonisen criterion as a pragmatic tool for determining clinical status.
Characteristics of patients included in the cohort analysis
| Disease | Patients | Sex | Age | Caste | Comorbidities | ||
| n (% of total) | Female | Male | Mean±SD | Bahun/Chhetri | Non-Bahun/ | n (%) | |
| Diabetes | 130 (22) | 28 (22) | 102 (78) | 55±12 | 78 (60) | 52 (40) | 50 (38) |
| Hypertension | 340 (57) | 166 (49) | 174 (51) | 56±11 | 200 (59) | 140 (41) | 70 (21) |
| COPD | 204 (34) | 138 (68) | 66 (32) | 59±11 | 117 (57) | 87 (43) | 45 (22) |
|
|
| ||||||
Total unique patients in NCD analysis cohort: 597.
COPD, chronic obstructive pulmonary disease; NCD, non-communicable disease.
Loss-to-follow-up and follow-up rates of cohort analysis patients
| NCD cohort | LTFU* | Facility (MLP) | Community (CHW) | Combined | ||
| Follow-up visits | Days between last two visits | Follow-up visits | Days between last two visits | Monthly touch-points per patient | ||
| (%) | Median | Median | Median | Median | Median | |
| Diabetes | 16 | 6 (44, 8) | 67 (38, 126) | 10 (44, 13) | 29 (2121, 41) | 0.9 (0.5, 1.2) |
| Hypertension | 19 | 6 (44, 9) | 62 (36, 111) | 10 (55, 13) | 30 (2525, 42) | 0.9 (0.6, 1.2) |
| COPD | 22 | 7 (44, 9) | 56 (34, 98) | 11 (66, 14) | 30 (2626, 39) | 0.9 (0.7, 1.3) |
*A patient was defined as LTFU if they never had a follow-up visit at the facility. These patients were excluded from the analysis cohort.
CHW, community health worker; COPD, chronic obstructive pulmonary disease; LTFU, lost to follow-up; MLP, mid-level practitioner; NCD, non-communicable disease.
Figure 2Change in proportion of cohort patients ‘at-goal’ status from baseline to endline, by condition. COPD, chronic obstructive pulmonary disease. *denote statistical significance.